S
Sandra Borkowski
Researcher at Bayer Corporation
Publications - 23
Citations - 1743
Sandra Borkowski is an academic researcher from Bayer Corporation. The author has contributed to research in topics: Prostate cancer & In vivo. The author has an hindex of 15, co-authored 23 publications receiving 1615 citations. Previous affiliations of Sandra Borkowski include Bayer HealthCare Pharmaceuticals & Bayer Schering Pharma AG.
Papers
More filters
Journal Article
Tumor Targeting by an Aptamer
Brian Hicke,Andrew W. Stephens,Ty A. Gould,Ying-Fon Chang,Cynthia K. Lynott,James Heil,Sandra Borkowski,Christoph-Stephan Hilger,Gary Cook,Stephen Warren,Paul Schmidt +10 more
TL;DR: TTA1 is taken up by a variety of solid tumors including breast, glioblastoma, lung, and colon, suggesting imaging and potentially therapeutic applications and rapid uptake by tumors and rapid clearance from the blood and other nontarget tissues enables clear tumor imaging.
Journal ArticleDOI
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function
Kathrin Schmidt,Sandra Borkowski,Jens Kurreck,Andrew Stephens,Rolf Bald,Maren Hecht,Matthias Friebe,Ludger Dinkelborg,Volker A. Erdmann +8 more
TL;DR: The strategy to introduce LNA modifications after the selection procedure is likely to be generally applicable to improve the in vivo stability of aptamers without compromising their binding properties.
Journal ArticleDOI
In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
Esa Kähkönen,Ivan Jambor,Jukka Kemppainen,Kaisa Lehtiö,Tove J. Grönroos,Anna Kuisma,Pauliina Luoto,H. Sipilä,Tuula Tolvanen,Kalle Alanen,Jonna Silén,Markku Kallajoki,Anne Roivainen,Niklaus Schäfer,Roger Schibli,Martina Dragic,Anass Johayem,Ray Valencia,Sandra Borkowski,Heikki Minn +19 more
TL;DR: BAY86-7548 PET/CT is a promising molecular imaging technique for detecting intraprostatic prostate cancer and has a sensitivity, specificity, and accuracy of 88, 81, and 83%, respectively, for detection of primary PCa and sensitivity for metastatic lymph nodes using histology as gold standard.
Journal ArticleDOI
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
Rosalba Mansi,Xuejuan Wang,Flavio Forrer,Flavio Forrer,Beatrice Waser,Renzo Cescato,Keith Graham,Sandra Borkowski,Jean Claude Reubi,Helmut R. Maecke,Helmut R. Maecke +10 more
TL;DR: A new conjugate, RM2, with the chelator DOTA coupled to D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 via the cationic spacer 4-amino-1-carboxymethyl-piperidine is described for labelling with radiometals such as 111In and 68Ga.
Journal ArticleDOI
Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate
Dietmar Berndorff,Sandra Borkowski,Stephanie Sieger,Axel Rother,Matthias Friebe,Francesca Viti,Christoph Stephan Hilger,John E. Cyr,Ludger Dinkelborg +8 more
TL;DR: Compared with other L19-basedRadioimmunoconjugates, I-131-L19-SIP is characterized by superior antitumor efficacy and toxicity profile in the F9 teratocarcinoma animal model, indicating that ED-B fibronectin-targeted radioimmunotherapy using I- 131-L 19-Sip has potential to be applied to treatment of solid cancers.